Accelerated porcine wound healing after treatment with α-gal nanoparticles

Plastic and Reconstructive Surgery

Volumn 129, Issue 2, 2012, Pages

  Hurwitz, Zachary M ^a   Ignotz, Ronald ^a   Lalikos, Janice F ^a   Galili, Uri ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYL EPITOPE; ALPHA-GALACTOSYL EPITOPE; NANOPARTICLE; TRISACCHARIDE;

ANIMAL; ARTICLE; DRUG EFFECT; SWINE; TIME; WOUND HEALING;

ANIMALS; NANOPARTICLES; SWINE; TIME FACTORS; TRISACCHARIDES; WOUND HEALING;

EID: 84856718065     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31823aebb1     Document Type: Article

References (37)

1. Leibovich SJ, Ross R. The role of the macrophage in wound repair: A study with hydrocortisone and antimacrophage serum. Am J Pathol. 1975;78:71-100.
2. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-740.
3. Martin P, Leibovich SJ. Inflammatory cells during wound repair: The good, the bad and the ugly. Trends Cell Biol. 2005;15:599-607.
4. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008;453:314-321.
5. Piccolo MT, Wang Y, Sannomiya P, et al. Chemotactic mediator requirements in lung injury following skin burns in rats. Exp Mol Pathol. 1999;66:220-226.
6. Low QE, Drugea IA, Duffner LA, et al. Wound healing in MIP-1 α(-/-) and MCP-1(-/-) mice. Am J Pathol. 2001; 159:457-463.
7. Shallo H, Plackett TP, Heinrich SA, Kovacs EJ. Monocyte chemoattractant protein-1 (MCP-1) and macrophage infiltration into the skin after burn injury in aged mice. Burns 2003;29:641-647.
8. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-β-galactosyl specificity. J Exp Med. 1984;160:1519-1531.
9. Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-β-galactosyl IgG: II. The specific recognition of α(1-3)-linked galactose residues. J Exp Med. 1985;162:573-582.
10. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the anti-Gal antibody and the Gal α1-3Gal epitope in primates. Proc Natl Acad Sci USA. 1987; 84:1369-1373.
11. Galili U, Shohet SB, Kobrin E, Stults CLM, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of β-galactosyl epitopes on nucleated cells. J Biol Chem. 1988;263:17755-17762.
12. Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal: β-DGal( 1,4)-D-GlcNAc α(1,3)-galactosyltransferase cDNA. J Biol Chem. 1990;265:7055-7061.
13. Galili U, Swanson K. Gene sequences suggest inactivation of α1-3 galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA. 1991;88:7401-7404.
14. Joziasse DH, Shaper JH, Jabs EW, Shaper NL. Characterization of an α1-3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene. J Biol Chem. 1991;266:6991-6998.
15. Koike C, Fung JJ, Geller DA, et al. Molecular basis of evolutionary loss of the α1,3-galactosyltransferase gene in higher primates. J Biol Chem. 2002;277:10114-10120.
16. Galili U. Interaction of the natural anti-Gal antibody with β-galactosyl epitopes: A major obstacle for xenotransplantation in humans. Immunol Today 1993;14:480-482.
17. Good H, Cooper DKC, Malcolm AJK, et al. Identification of carbohydrate structures which bind human anti-porcine Abs: Implications for discordant grafting in man. Transplant Proc. 1992;24:559-562.
18. Sandrin M, Vaughan HA, Dabkowski PL, McKenzie IF. Antipig IgM antibodies in human serum react predominantly with Gal α1-3Gal epitopes. Proc Natl Acad Sci USA. 1993;90: 11391-11395.
19. Collins BH, Cotterell AH, McCurry KR, et al. Cardiac xenografts between primate species provide evidence for the importance of β-galactosyl determinant in hyperacute rejection. J Immunol. 1995;154:5500-5510.
20. Sachs DH, Sykes M, Robson SC, Cooper DK. Xenotransplantation. Adv Immunol. 2001;79:129-223.
21. Snyderman R, Pike MC. Chemoattractant receptors on phagocytic cells. Annu Rev Immunol. 1984;2:257-281.
22. Damerau B. Biological activities of complement-derived peptides. Rev Physiol Biochem Pharmacol. 1987;108:151-206.
23. Galili U, Wigglesworth K, Abdel-Motal UM. Intratumoral injection of β-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol. 2007;178:4676-4687.
24. Galili U, Wigglesworth K, Abdel-Motal UM. Accelerated healing of skin burns by anti-Gal/ β-gal liposomes interaction. Burns 2010;36:239-251.
25. Wigglesworth K, Racki WJ, Mishra R, Szomolany-Tsuda E, Greiner DL, Galili U. Rapid recruitment and activation of macrophages by anti-Gal/ β-gal liposome interaction accelerates wound healing. J Immunol. 2011;186:4422-4432.
26. Phelps CJ, Koike C, Vaught TD, et al. Production of α1,3- galactosyltransferase-deficient pigs. Science 2003;299:411-414.
27. Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3- galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med. 2004;11:32-34.
28. ByrneGW,StalboergerPG,Davila E, et al.Proteomicidentification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation 2008;15:268-276.
29. Yeh P, Ezzelarab M, Bovin N, et al. Investigation of potential carbohydrate antigen targets for human and baboon antibodies. Xenotransplantation 2010;17:197-206.
30. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290.
31. Tanemura M, Yin D, Chong AS, Galili U. Differential immune response to β-gal epitopes on xenografts and allografts: Implications for accommodation in xenotransplantation. J Clin Invest. 2000;105:301-310.
32. Danon D, Madjar J, Edinov E, et al. Treatment of human ulcers by application of macrophages prepared from a blood unit. Exp Gerontol. 1997;32:633-641.
33. Orenstein A, Kachel E, Zuloff-Shani A, et al. Treatment of deep sternal wound infections post-open heart surgery by application of activated macrophage suspension. Wound Repair Regen. 2005;13:237-242.
34. Manches O, Plumas J, Lui L, et al. Anti-Gal mediated targeting of human B lymphoma cells to antigen-presenting cells: A potential method for immunotherapy with autologous tumor cells. Haematologica 2005;90:625-634.
35. Minatoguchi S, Takemura G, Chen XH, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004;109:2572-2580.
36. Dewald O, Zymek P, Winkelmann K, et al. CCL2/monocyte chemoattractant protein-1 regulatesinflammatoryresponses critical to healing myocardial infarcts. Circ Res. 2005;96:881-889.
37. Miura T, Whittaker P, Miki T, et al. Macrophage colonystimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair. J Am Coll Cardiol. 2006;47:626-634.